Choosing a PDMO^® for your programme

Infographic1 min read 19th Jul 2021

Share via email Share via LinkedIn

Choosing a PDMO® for your programme

Share via email Share via LinkedIn

Popular articles

Whitepaper7 min read

Scaling ring-closing metathesis in API development: Challenges and success factors Read more

ADC manufacturing facilities at Sterling Pharma Solutions' Deeside, Wales facilities

Blog7 min read

Top 5 considerations in ADC clinical manufacturing Read more

HPAPI capabilities at Germantown, Wisconsin

One pager5 min read

HPAPI development and manufacture: From medicinal chemistry to process chemistry Read more

Scott Bruce - Head of Production

Spotlight5 min read

Scientist Snapshot | Scott Bruce, Head of Production Read more

Infographic1 min read

Solid form development: Evaluating salt hits against free API to achieve an optimal target form Read more

Sterling scientist in the lab using HPLCs

Blog6 min read

Deuteration in API development: Synthetic, analytical and engineering considerations Read more

Sign up for updates

Be the first to see the latest articles and updates from industry leaders, delivered straight to your inbox

Company

This field is for validation purposes and should be left unchanged.

Name(Required)

Email(Required)

Company Name(Required)

This field is hidden when viewing the form

Prospect Source

Please click here for our privacy policy

Service. Passion. Science.

PDMO^® is registered in the U.S. Patent and Trademark Office.

PDMO^® is a registered trademark of Sterling Pharma Solutions Limited (EUIPO and UKIPO). All rights reserved.

Sterling Pharma Solutions Limited. Registration number: 05712796. Registered office address: Dudley Lane, Dudley, Cramlington, NE23 7QG, United Kingdom. Registered in England.
VAT number: GB320549229